GNBT - Generex Biotechnology Discusses Coronavirus Solutions with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - February 6, 2020) - The Stock Day Podcast welcomed Generex Biotechnology (OTCQB: GNBT) ("the Company"), an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Joseph Moscato and Dr. Eric Von Hofe joined Stock Day host Everett Jolly.
Jolly began the interview by commenting on the implications of the Coronavirus, and asked about the Company's solutions for these issues. "The Coronavirus is getting to pandemic proportions, it's growing each and every day," explained Moscato. "Generex's background in infectious diseases is very vast and wide," he continued. "We've done a lot of work in Ebola, Bird Flu, Swine Flu, Influenza, and Avian Flu," explained Moscato, adding that the Company's vaccine technology has been very successful.
Dr. Hofe then expanded on the Company's vaccine technology, as well as their experience with diseases similar to the Coronavirus. "There's definitely an uptick in these types of viruses," explained Dr. Hofe. "What we have is a synthetic peptide vaccine that is modified to stimulate the immune system," said Dr. Hofe, adding that this type of vaccine is easier and quicker to make compared to traditional alternatives. "It's definitely getting a lot more attention now."
Jolly then asked about the Company's current technology and if it could represent a solution for the Coronavirus. "We're not just talking, we've done it before," said Moscato. "We have a proven track record," he added, noting that because of the Company's extensive experience in this space, they are able to bypass animal testing. He further explained that the Company's vaccine process is quick and inexpensive.
"How long would it take you to develop a vaccine? And can you compare it to the other technologies that are being developed out there?", asked Jolly. "We worked on the SARS outbreak, which is also a Coronavirus, about 20 years ago, and there's about an 80% homology between SARS and the current Coronavirus," explained Dr. Hofe. "I would say in about one month we could get these peptides made, test them in the blood of people who have recovered from the Coronavirus, and within three months have clinical material ready for some studies," he explained.
Moscato then noted that the Company's timeline for the release of a vaccine would be accelerated compared to other competitors on the market since they are able to bypass animal testing.
To close the interview, Moscato shared that the Company is currently pursuing potential partnerships in an effort to utilize their technology as a solution for the Coronavirus. "We are already in the process of talking and consummating a technology deal with a lab that has identified the episcope for the Coronavirus," said Moscato, adding that the Company is also in discussions with companies in China to deploy the technology. "It's an exciting time for Generex Biotechnology," closed Moscato.
To hear the entire interview with Generex Biotechnology, follow the link to the podcast here: https://audioboom.com/posts/7497034-generex-biotechnology-discusses-coronavirus-solutions-with-the-stock-day-podcast
Also, you can check out the video presentation below:
https://www.youtube.com/watch?v=uiHRa5hDrnw&feature=youtu.be
Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
investor@generex.com
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
SOURCE:
Stock Day Media
602-441-3474
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/52190